Related references
Note: Only part of the references are listed.Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study
Carlo Visco et al.
LEUKEMIA (2021)
Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and CAR-T Cell Therapy
Miriam Marangon et al.
CANCERS (2021)
Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial
Steven Le Gouill et al.
BLOOD (2021)
Allogeneic stem cell transplantation in patients with mantle cell lymphoma: results from the MANTLE-FIRST study on behalf of Fondazione Italiana Linfomi
Annalisa Arcari et al.
LEUKEMIA & LYMPHOMA (2021)
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
Anthony R Mato et al.
LANCET (2021)
Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term
Sergio Cortelazzo et al.
BONE MARROW TRANSPLANTATION (2021)
Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances
Tingyu Wen et al.
LEUKEMIA (2021)
KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study
Simone Ferrero et al.
HAEMATOLOGICA (2020)
Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk
Markus C. Stuehlinger et al.
WIENER KLINISCHE WOCHENSCHRIFT (2020)
p53 is associated with high-risk and pinpointsTP53missense mutations in mantle cell lymphoma
Joana M. Rodrigues et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma
David A. Bond et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2020)
Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis
Holly A. Hill et al.
BLOOD ADVANCES (2020)
Genetic heterogeneity and prognostic impact of recurrent ANK2 and TP53 mutations in mantle cell lymphoma: a multi-centre cohort study
Seri Jeong et al.
SCIENTIFIC REPORTS (2020)
Predictors of Tyrosine Kinase Inhibitor Use Among Older Patients with Chronic Myeloid Leukemia in the United States
Rong Wang et al.
BLOOD (2020)
Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties
Peter Dreger et al.
BONE MARROW TRANSPLANTATION (2019)
The use of ibrutinib before and after allogeneic stem cell transplantation
Massimo Martino et al.
EXPERT OPINION ON ORPHAN DRUGS (2019)
UPDATED SAFETY AND EFFICACY DATA IN THE PHASE 1 TRIAL OF PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) TREATED WITH BRUTON TYROSINE KINASE (BTK) INHIBITOR ZANUBRUTINIB (BGB-3111)
C.S. Tam et al.
HEMATOLOGICAL ONCOLOGY (2019)
P16, c-Myc, SOX11, P53, ki67 and CD71Protein Expression in Aggressive Morphological Variants of Mantle Cell Lymphomas Compared to Classical Morphological Mantle Cell Lymphomas in Multiple Clinical Trials
Barbara Burroni et al.
BLOOD (2019)
Long-Term Outcomes with Ibrutinib Versus the Prior Regimen: A Pooled Analysis in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) with up to 7.5 Years of Extended Follow-up
Simon Rule et al.
BLOOD (2019)
Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma
Simon Rule et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death
Carlo Visco et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Guideline for the management of mantle cell lymphoma
Pamela McKay et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding
Giuseppe Boriani et al.
HEMATOLOGICAL ONCOLOGY (2018)
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial
Michael Wang et al.
LANCET (2018)
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
Constantine S. Tam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial
Mats Jerkeman et al.
LANCET HAEMATOLOGY (2018)
Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies
Simon Rule et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy
Christian W. Eskelund et al.
BLOOD (2017)
15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau
Christian W. Eskelund et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Paulus Kirchhof et al.
EUROPEAN HEART JOURNAL (2016)
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase study
Martin Dreyling et al.
LANCET (2016)
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results
Michael L. Wang et al.
BLOOD (2015)
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M. Dreyling et al.
ANNALS OF ONCOLOGY (2014)
Autologous or Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Chemotherapy-Sensitive Mantle-Cell Lymphoma: Analysis of Transplantation Timing and Modality
Timothy S. Fenske et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael L. Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Share Paper
